MedPath

A Safety and Efficacy Extension Study of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis

Phase 2
Conditions
Relapsing-Remitting Multiple Sclerosis
Registration Number
JPRN-jRCT2080221270
Lead Sponsor
ONO PHARMACEUTICAL CO.,LTD.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
343
Inclusion Criteria

Completed 26 weeks of double-blind phase of Study ONO-4641POU006

Exclusion Criteria

Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath